Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
LONDON - Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), a company specializing in longevity research, announced its Annual General Meeting (AGM) will take place at 9 a.m. on June 12, 2025, at One Heddon Street, London. The notice and proxy forms for the AGM will be accessible on the company’s website and were sent to shareholders on May 19, 2025.
The AGM will follow the release of Genflow’s Annual Report and Accounts for the year ending December 31, 2024, which have been available on the company’s website since April 30, 2025, and were distributed to registered shareholders.
Genflow, established in 2020 and headquartered in the UK with R&D facilities in Belgium, focuses on developing gene therapies aimed at slowing down the aging process. The company’s primary research involves GF-1002, a gene therapy based on a variant of the SIRT6 gene associated with longevity. Preclinical results for GF-1002 have shown promise, and clinical trials are scheduled to begin in 2025 to investigate its potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a common chronic liver disease currently lacking effective treatments.
This information is based on a press release statement and is intended to provide shareholders and the public with essential details regarding the upcoming AGM and the company’s ongoing research endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.